Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes

por Møller, Alexandra Louise, Thöni, Stefanie, Keller, Felix, Sharifli, Samir, Rasmussen, Daniel Guldager Kring, Genovese, Federica, Karsdal, Morten Asser, Mayer, Gert
Publicado 2023

Endotrophin as a risk marker of mortality and kidney complications in a type 1 diabetes cohort

por Møller, Alexandra Louise, Tougaard, Ninna Hahn, Rasmussen, Daniel Guldager Kring, Genovese, Federica, Rønn, Pernille Falberg, Hansen, Tine Willum, Karsdal, Morten Asser, Rossing, Peter
Publicado 2023